[1] Dandachi D, Ostrom QT, Chong I, Serpa JA, Giordano TP, Kruchko C et al. Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data. Cancer Causes Control 2019;30:477-488.
[2] Haldorsen IS, Krossnes BK, Aarseth JH, Scheie D, Johannesen TB, Mella O et al. Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989-2003 : time trends in a 15-year national survey. Cancer 2007;110:1803-1814.
[3] Krogh-Jensen M, D'Amore F, Jensen MK, Christensen BE, Thorling K, Pedersen M et al. Clinicopathological features, survival and prognostic factors of primary central nervous system lymphomas: trends in incidence of primary central nervous system lymphomas and primary malignant brain tumors in a well-defined geographical area. Population-based data from the Danish Lymphoma Registry, LYFO, and the Danish Cancer Registry. Leuk Lymphoma 1995;19:223-233.
[4] Shiels MS, Pfeiffer RM, Besson C, Clarke CA, Morton LM, Nogueira L et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol 2016;174:417-424.
[5] Shin SH, Jung KW, Ha J, Lee SH, Won YJ, Yoo H. Population-based Incidence and Survival for Primary Central Nervous System Lymphoma in Korea, 1999-2009. Cancer Res Treat 2015;47:569-574.
[6] van der Meulen M, Dinmohamed AG, Visser O, Doorduijn JK, Bromberg JEC. Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989-2015. Leukemia 2017;31:1822-1825.
[7] Pulido JS, Vierkant RA, Olson JE, Abrey L, Schiff D, O'Neill BP. Racial differences in primary central nervous system lymphoma incidence and survival rates. Neuro Oncol 2009;11:318-322.
[8] Eloranta S, Branvall E, Celsing F, Papworth K, Ljungqvist M, Enblad G et al. Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000-2013. Eur J Haematol 2018;100:61-68.
[9] Deckert M, Engert A, Bruck W, Ferreri AJ, Finke J, Illerhaus G et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia 2011;25:1797-1807.
[10] Martinez-Calle N, Poynton E, Alchawaf A, Kassam S, Horan M, Rafferty M et al. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival. Br J Haematol 2020;.
[11] Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 2016;3:217.
[12] Phillips EH, Fox CP, Cwynarski K. Primary CNS lymphoma. Curr Hematol Malig Rep 2014;9:243-253.
[13] Schlegel U, Pels H, Glasmacher A, Kleinschmidt R, Schmidt-Wolf I, Helmstaedter C et al. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatry 2001;71:118-122.
[14] Finnish Cancer Registry [Internet]. Helsinki, Finland; 2021 [cited 2021 Jan 30]. Available from: https://cancerregistry.fi/
[15] Pohjois-Suomen terveydenhuollon tukisäätiö [Internet]. Oulu, Finland; 2021 [cited 2021 Feb 8]. Available from: https://terttusaatio.fi
[16] Cancer Society of Finland [Internet]. Helsinki, Finland; 2021 [cited 2021 Jan 30]. Available from: https://www.cancersociety.fi/
[17] Finnish Institute for Health and Welfare [Internet]. Helsinki, Finland; 2021 [cited 2021 Jan 30]. Available from: https://thl.fi/en/web/thlfi-en
[18] Leinonen MK, Rantanen M, Pitkaniemi J, Malila N. Coverage and accuracy of myeloproliferative and myelodysplastic neoplasms in the Finnish Cancer Registry. Acta Oncol 2016;55:782-786.
[19] Danckert B, Ferlay J, Engholm G , Hansen HL, Johannesen TB, Khan S, Køtlum JE, Ólafsdóttir E, Schmidt LKH, Virtanen A and Storm HH. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 8.2 (26.03.2019). 2020.
[20] Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A et al. NORDCAN--a Nordic tool for cancer information, planning, quality control and research. Acta Oncol 2010;49:725-736.
[21] Brenner H, Hakulinen T. Long-term cancer patient survival achieved by the end of the 20th century: most up-to-date estimates from the nationwide Finnish cancer registry. Br J Cancer 2001;85:367-371.
[22] Brenner H, Soderman B, Hakulinen T. Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland. Int J Epidemiol 2002;31:456-462.
[23] Mendez JS, Ostrom QT, Gittleman H, Kruchko C, DeAngelis LM, Barnholtz-Sloan JS et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol 2018;20:687-694.
[24] Statistics Finland. Population of Finland in 2007 [Internet]. Statistics Finland; Helsinki, Finland; 2008 March 28 [cited 2021 Jan 30]. Available from: https://www.stat.fi/til/vaerak/2007/vaerak_2007_2008-03-28_tie_001_en.html
[25] Statistics Finland. Population of Finland in 2017 [Internet]. Statistics Finland; Helsinki, Finland; 2018 March 29 [cited 2021 Jan 30]. Available from: https://www.stat.fi/til/vaerak/2017/vaerak_2017_2018-03-29_tie_001_en.html
[26] Velasco R, Mercadal S, Vidal N, Alana M, Barcelo MI, Ibanez-Julia MJ et al. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. J Neurooncol 2020;.
[27] Finnish Institute of Health and Welfare. Statistical database of the National Infectious Diseases Register. 2020.
[28] Locke AE, Steinberg KM, Chiang CWK, Service SK, Havulinna AS, Stell L et al. Author Correction: Exome sequencing of Finnish isolates enhances rare-variant association power. Nature 2019;575:E4-x.
[29] Ponzoni M, Issa S, Batchelor TT, Rubenstein JL. Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. Ann Oncol 2014;25:316-322.
[30] Furst T, Hoffman H, Chin LS. All-cause and tumor-specific mortality trends in elderly primary central nervous system lymphoma (PCNSL) patients: a surveillance, epidemiology, and end results (SEER) analysis. J Neurosurg Sci 2019;.
[31] Harjama L, Kuitunen H, Turpeenniemi-Hujanen T, Haapasaari KM, Leppa S, Mannisto S et al. Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study. Acta Oncol 2015;54:939-943.
[32] Biccler JL, Savage KJ, Brown PDN, Jorgensen J, Larsen TS, Poulsen CB et al. Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma. Leuk Lymphoma 2019;60:2516-2523.
[33] Yamanaka R, Morii K, Shinbo Y, Sano M, Homma J, Tsuchiya N et al. Late relapse of primary central nervous system lymphoma. Leuk Lymphoma 2017;58:475-477.